Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice

Neuroscience

Volumn 218, Issue , 2012, Pages 185-195

  Del Boca, C ^a   Lutz, P E ^a   Le Merrer, J ^a   Koebel, P ^a   Kieffer, B L ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Adeno associated viral vector; Anxiety; Baso lateral amygdala; Cholecystokinin; Depression; Short hairpin RNA

Indexed keywords

CHOLECYSTOKININ; NALOXONE; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; AVERSION; BASOLATERAL AMYGDALA; BRAIN TISSUE; CONTROLLED STUDY; DOWN REGULATION; EMOTION; FLUORESCENCE IN SITU HYBRIDIZATION; FORCED SWIMMING TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANQUILIZING ACTIVITY;

AMYGDALA; ANIMALS; ANXIETY; CHOLECYSTOKININ; DEPRESSION; GENE KNOCKDOWN TECHNIQUES; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84863782289     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.05.022     Document Type: Article

References (53)

1. Ambesi-Impiombato A., D'Urso G., Muscettola G., de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Res Brain Res Protoc 2003, 11:189-196.
2. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., Benoliel J.J. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 2008, 13:1079-1092.
3. Beinfeld M.C. An introduction to neuronal cholecystokinin. Peptides 2001, 22:1197-1200.
4. Belcheva I., Belcheva S., Petkov V.V., Petkov V.D. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala. Neuropharmacology 1994, 33:995-1002.
5. Berna M.J., Tapia J.A., Sancho V., Jensen R.T. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol 2007, 7:583-592.
6. Bradwejn J., Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 2001, 234:19-27.
7. Cain B.M., Connolly K., Blum A., Vishnuvardhan D., Marchand J.E., Beinfeld M.C. Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J Comp Neurol 2003, 467:307-325.
8. Chen Q., Tang M., Mamiya T., Im H.I., Xiong X., Joseph A., Tang Y.P. Bi-directional effect of cholecystokinin receptor-2 overexpression on stress-triggered fear memory and anxiety in the mouse. PLoS One 2010, 5:e15999.
9. Chotteau-Lelievre A., Dolle P., Gofflot F. Expression analysis of murine genes using in situ hybridization with radioactive and nonradioactively labeled RNA probes. Methods Mol Biol 2006, 326:61-87.
10. Chung L., Moore S.D. Cholecystokinin excites interneurons in rat basolateral amygdala. J Neurophysiol 2009, 102:272-284.
11. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
12. Dauge V., Sebret A., Beslot F., Matsui T., Roques B.P. Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 2001, 25:690-698.
13. Duangdao D.M., Clark S.D., Okamura N., Reinscheid R.K. Behavioral phenotyping of neuropeptide S receptor knockout mice. Behav Brain Res 2009, 205:1-9.
14. Eser D., Uhr M., Leicht G., Asmus M., Langer A., Schule C., Baghai T.C., Mulert C., Rupprecht R. Glyoxalase-I mRNA expression and CCK-4 induced panic attacks. J Psychiatr Res 2011, 45:60-63.
15. Frankland P.W., Josselyn S.A., Bradwejn J., Vaccarino F.J., Yeomans J.S. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci 1997, 17:1838-1847.
16. Frenois F., Cador M., Caille S., Stinus L., Le Moine C. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 2002, 16:1377-1389.
17. Frenois F., Stinus L., Di Blasi F., Cador M., Le Moine C. A specific limbic circuit underlies opiate withdrawal memories. J Neurosci 2005, 25:1366-1374.
18. Goeldner C., Lutz P.E., Darcq E., Halter T., Clesse D., Ouagazzal A.M., Kieffer B.L. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 2011, 69:236-244.
19. Hebb A.L., Poulin J.F., Roach S.P., Zacharko R.M., Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1225-1238.
20. Hernando F., Fuentes J.A., Fournie-Zaluski M.C., Roques B.P., Ruiz-Gayo M. Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system. Eur J Pharmacol 1996, 318:221-229.
21. Holmes A., Kinney J.W., Wrenn C.C., Li Q., Yang R.J., Ma L., Vishwanath J., Saavedra M.C., Innerfield C.E., Jacoby A.S., Shine J., Iismaa T.P., Crawley J.N. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 2003, 28:1031-1044.
22. Jasnow A.M., Ressler K.J., Hammack S.E., Chhatwal J.P., Rainnie D.G. Distinct subtypes of cholecystokinin (CCK)-containing interneurons of the basolateral amygdala identified using a CCK promoter-specific lentivirus. J Neurophysiol 2009, 101:1494-1506.
23. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
24. Kulkarni S.K., Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1248-1254.
25. Le Merrer J., Plaza-Zabala A., Del Boca C., Matifas A., Maldonado R., Kieffer B.L. Deletion of the delta opioid receptor gene impairs place conditioning but preserves morphine reinforcement. Biol Psychiatry 2011, 69:700-703.
26. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 2000, 23:155-184.
27. Lu L., Zhang B., Liu Z., Zhang Z. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 2002, 954:132-140.
28. Mascagni F., McDonald A.J. Immunohistochemical characterization of cholecystokinin containing neurons in the rat basolateral amygdala. Brain Res 2003, 976:171-184.
29. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
30. McIlwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiol Behav 2001, 73:705-717.
31. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 1999, 23(4):591-613.
32. Meziane H., Devigne C., Tramu G., Soumireu-Mourat B. Distribution of cholecystokinin immunoreactivity in the BALB/c mouse forebrain: an immunocytochemical study. J Chem Neuroanat 1997, 12:191-209.
33. Miller B.H., Schultz L.E., Gulati A., Su A.I., Pletcher M.T. Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety. PLoS One 2010, 5:e14458.
34. Mineur Y.S., Belzung C., Crusio W.E. Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav Brain Res 2006, 175:43-50.
35. Mitchell J.M., Bergren L.J., Chen K.S., Fields H.L. Cholecystokinin is necessary for the expression of morphine conditioned place preference. Pharmacol Biochem Behav 2006, 85:787-795.
36. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 1968, 6:156-162.
37. Noble F., Roques B.P. Phenotypes of mice with invalidation of cholecystokinin (CCK(1) or CCK(2)) receptors. Neuropeptides 2002, 36:157-170.
38. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999, 51:745-781.
39. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press. 2nd ed.
40. Pommier B., Beslot F., Simon A., Pophillat M., Matsui T., Dauge V., Roques B.P., Noble F. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. J Neurosci 2002, 22:2005-2011.
41. Ramos A. Animal models of anxiety: do I need multiple tests?. Trends Pharmacol Sci 2008, 29(10):493-498.
42. Raud S., Innos J., Abramov U., Reimets A., Koks S., Soosaar A., Matsui T., Vasar E. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 2005, 181:347-357.
43. Renard C.E., Dailly E., David D.J., Hascoet M., Bourin M. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 2003, 17:449-455.
44. Rotzinger S., Lovejoy D.A., Tan L.A. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010, 31:736-756.
45. Schiffmann S.N., Vanderhaeghen J.J. Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J Comp Neurol 1991, 304:219-233.
46. Sherrin T., Todorovic C., Zeyda T., Tan C.H., Wong P.T., Zhu Y.Z., Spiess J. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Mol Psychiatry 2009, 14:291-307.
47. Shindo S., Yoshioka N. Polymorphisms of the cholecystokinin gene promoter region in suicide victims in Japan. Forensic Sci Int 2005, 150:85-90.
48. Turri M.G., Datta S.R., DeFries J., Henderson N.D., Flint J. QTL analysis identifies multiple behavioral dimensions in ethological tests of anxiety in laboratory mice. Curr Biol 2001, 11(10):725-734.
49. Valverde O., Roques B.P. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Neurosci Lett 1998, 244:37-40.
50. van Gaalen M.M., Steckler T. Behavioural analysis of four mouse strains in an anxiety test battery. Behav Brain Res 2000, 115(1):95-106.
51. Voikar V., Vasar E., Rauvala H. Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice. implications for phenotyping screens. Genes Brain Behav 2004, 3:27-38.
52. Wang H., Spiess J., Wong P.T., Zhu Y.Z. Blockade of CRF1 and CCK2 receptors attenuated the elevated anxiety-like behavior induced by immobilization stress. Pharmacol Biochem Behav 2011, 98:362-368.
53. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28:158-167.